Biotalys
Biotalys NV (formerly Agrosavfe) is a rapidly growing and transformative food and crop protection company developing a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Based on its groundbreaking technology platform, Biotalys has developed a broad pipeline of effective and safe products that address key crop pests and diseases. Combining the high-performance characteristics and consistency of chemicals with the clean safety profile of biologicals, Biotalys provides ideal crop protection agents for both pre-and post-harvest applications. Biotalys’ lead biofungicide, BioFun-1, has demonstrated consistent, high efficacy against major pests in a global fruit and vegetables field trial. The company expects to launch BioFun-1 in the U.S. in 2022, followed by global market introductions.
Sector
Industrial Biotech
Strategy
Industrial Biotech
Status
Live
Website
biotalys.com
Related News
Biotalys appoints Kamal El Mernissi as Chief Business Development Officer
Biotalys announces closing of private placement
Biotalys receives approval for large-scale demonstration trials of EVOCA in the Netherlands
Biotalys starts field trials for second Biofungicide
Biotalys appoints Laura J. Meyer to Board of Directors
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.